Last 2.44 NOK
Change Today +0.04 / 1.67%
Volume 16.5K
As of 7:05 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

aqualis asa (AQUA) Snapshot

Open
2.40 NOK
Previous Close
2.40 NOK
Day High
2.47 NOK
Day Low
2.40 NOK
52 Week High
02/25/14 - 3.31 NOK
52 Week Low
07/1/13 - 1.13 NOK
Market Cap
343.0M
Average Volume 10 Days
301.8K
EPS TTM
-2.04 NOK
Shares Outstanding
140.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AQUALIS ASA (AQUA)

Related News

No related news articles were found.

aqualis asa (AQUA) Related Businessweek News

No Related Businessweek News Found

aqualis asa (AQUA) Details

Aqualis ASA operates in the marine and offshore, and healthcare sectors. The company is involved in developing drugs comprising CP-4200, a LVT derivative of azacytidine, which pre-dominantly acts as a modifier of gene expression; and CP-4033, a ribavirin elaidate, the LVT derivative of ribavirin that is in pre-clinical development for aggressive thyroid cancer. It also provides specialist marine and engineering consultancy services for the offshore oil and gas industry, including concept, FEED, and basic design engineering services for upgrades and conversion of jack-ups, FPSOs, and rigs; and marine warranty services, transportation and installation, rig moving, dynamic positioning, construction supervision, and due diligence services. The company was formerly known as Clavis Pharma ASA and changed its name to Aqualis ASA in October 2013. Aqualis ASA was founded in 2001 and is based in Oslo, Norway.

78 Employees
Last Reported Date: 02/26/14
Founded in 2001

aqualis asa (AQUA) Top Compensated Officers

Acting Chief Executive Officer
Total Annual Compensation: 1.3M NOK
Chief Business Officer of Healthcare
Total Annual Compensation: 1.3M NOK
Chief Business Officer
Total Annual Compensation: 1.4M NOK
Compensation as of Fiscal Year 2012.

aqualis asa (AQUA) Key Developments

Aqualis ASA Announces New Appointment

Aqualis ASA at its Extraordinary General Meeting, which was held February 27, 2014, has elected Glen Rodland as new chairman of the Board. Reuben Segal is elected as new Director and Martin Nes is elected as Deputy Director.

Aqualis ASA Approves Changes to Articles of Association

Aqualis ASA announced that at its EGM held on February 27, 2014, the shareholders approved the changes to the articles of association.

Aqualis ASA Announces Consolidated Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Aqualis ASA announced consolidated unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported revenues of NOK 13,689,000. Total operating income was NOK 14,450,000 compared with NOK 49,801,000 for the same period a year ago. Operating loss was NOK 4,334,000 compared with operating income of NOK 1,664,000 for the same period a year ago. Loss before tax was NOK 3,892,000 compared with profit before tax of NOK 3,437,000 for the same period a year ago. Loss for the period was NOK 3,892,000 or NOK 0.0 per basic and diluted share compared with profit for the period of NOK 3,437,000 or NOK 0.1 per basic and diluted share for the same period a year ago. Net cash used in operating activities was NOK 16,014,000 compared with NOK 38,422,000 for the same period a year ago. Purchase of plant, equipments and intangibles was NOK 5,648,000 compared with NOK 1,079,000 for the same period a year ago. For the full year, the company reported revenues of NOK 14,347,000. Total operating income was NOK 18,235,000 compared with NOK 84,981,000 for the same period a year ago. Operating loss was NOK 91,820,000 compared with NOK 103,994,000 for the same period a year ago. Loss before tax was NOK 87,545,000 compared with NOK 95,706,000 for the same period a year ago. Loss for the period was NOK 87,545,000 or NOK 2.1 per basic and diluted share compared with NOK 95,706,000 or NOK 2.9 per basic and diluted share for the same period a year ago. Net cash used in operating activities was NOK 156,041,000 compared with NOK 162,309,000 for the same period a year ago. Purchase of plant, equipments and intangibles was NOK 5,648,000 compared with NOK 1,393,000 for the same period a year ago. period from the company was acquired. In the fourth quarter and full year 2012 the operating income was mainly made up of deferred up-front fees recognised as income relating to an out-licensing agreement with Clovis Oncology, as well as government grants.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AQUA:NO 2.44 NOK +0.04

AQUA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AQUA.
View Industry Companies
 

Industry Analysis

AQUA

Industry Average

Valuation AQUA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.0x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AQUALIS ASA, please visit www.aqualis.no. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.